QB3@953, a San Francisco, USA-based incubator created by QB3, a University of California research institute and biotech accelerator, has announced an agreement with UK pharma company GlaxoSmithKline (LSE: GSK).
Together the companies will identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients. It formalizes an existing relationship between QB3@953 and GSK’s Discovery Partnerships with Academia team.
QB3@953 will work closely with GSK to identify innovators exploring targets with therapeutic potential and a defined clinical hypothesis, and will help facilitate collaborations between their researchers and GSK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze